This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Dementias  • Neuropathology  • Alert me on articles by topic

Arch Neurol. 1999;56:655-656.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

BIOLOGICAL MARKERS of Alzheimer disease (AD) have been intensively pursued during the past decade. The quest has been fueled by gains in our knowledge of AD brain pathology and its molecular underpinnings, providing important ideas about what to measure in patients to support diagnosis and treatment. There are 2 major thrusts at present. Neuroimaging techniques provide structural or metabolic information about the brain and have identified atrophy or decreased blood flow in the hippocampus and other brain areas as indices that discriminate between patients with AD and elderly control patients. Studies examining biochemical markers related to the neuropathology of AD have identified several promising candidates in cerebrospinal fluid (CSF). A recent consensus report of an expert working group¹ highlighted the need to develop and refine methods for early and accurate detection of AD, surveyed potential uses of biological markers, and proposed criteria to evaluate diagnostic markers.

Against this background, the . . . [Full Text of this Article]

RELATED ARTICLE

Cerebrospinal Fluid -Amyloid_(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease
Niels Andreasen, Camilla Hesse, Pia Davidsson, Lennart Minthon, Anders Wallin, Bengt Winblad, Hugo Vanderstichele, Eugeen Vanmechelen, and Kaj Blennow
Arch Neurol. 1999;56(6):673-680.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

What the Study of Persons At Risk for Familial Alzheimer's Disease Can Tell Us About the Earliest Stages of the Disorder: A Review
Ringman
J Geriatr Psychiatry Neurol 2005;18:228-233.
ABSTRACT  

Increased Cerebrospinal Fluid Levels of 3,3',5'-Triiodothyronine in Patients with Alzheimer's Disease
Sampaolo et al.
J. Clin. Endocrinol. Metab. 2005;90:198-202.
ABSTRACT | FULL TEXT  

Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients : An Ultrasensitive Bienzyme-Substrate-Recycle Enzyme-Linked Immunosorbent Assay
Hu et al.
Am. J. Pathol. 2002;160:1269-1278.
ABSTRACT | FULL TEXT  

Current Concepts in Mild Cognitive Impairment
Petersen et al.
Arch Neurol 2001;58:1985-1992.
ABSTRACT | FULL TEXT